Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 114, Issue 38, Pages 10268-10273Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1704143114
Keywords
developmental disorder; Down syndrome; neurogenesis
Categories
Funding
- Japan Agency for Medical Research and Development (AMED)
- AMED-CREST (Create Revolutionary Technological Seeds for Science and Technology Innovation)
- Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan
- Ministry of Health, Labour and Welfare of Japan
- Platform for Drug Discovery, Informatics, and Structural Life Science of MEXT, Japan
- Mochida Memorial Foundation
- Grants-in-Aid for Scientific Research [16H05926, 16K01932, 16K17907, 15H05721, 21249013] Funding Source: KAKEN
Ask authors/readers for more resources
Down syndrome (DS) caused by trisomy of chromosome 21 is the most common genetic cause of intellectual disability. Although the prenatal diagnosis of DS has become feasible, there are no therapies available for the rescue of DS-related neurocognitive impairment. A growth inducer newly identified in our screen of neural stem cells (NSCs) has potent inhibitory activity against dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) and was found to rescue proliferative deficits in Ts65Dn-derived neurospheres and human NSCs derived from individuals with DS. The oral administration of this compound, named ALGERNON (altered generation of neurons), restored NSC proliferation in murine models of DS and increased the number of newborn neurons. Moreover, administration of ALGERNON to pregnant dams rescued aberrant cortical formation in DS mouse embryos and prevented the development of abnormal behaviors in DS offspring. These data suggest that the neurogenic phenotype of DS can be prevented by ALGERNON prenatal therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available